Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
Iscalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40/TNFRSF5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Iscalimab (CFZ533) is a new, fully humanized monoclonal antibody that targets cluster of differentiation 40 (CD40), which can regulate the CD40-CD154 costimulatory pathway and prevent CD40 pathway signal transduction and CD40+ cell type activation. It is expected Become a new treatment for solid organs and related autoimmune diseases.
Ravagalimab is a humanized monoclonal antibody biosimilar expressed in CHO cells, targeting CD40/TNFRSF, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Golimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFA/TNF alpha, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U. S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Priliximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD4, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Tepoditamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/CLEC12A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Inebilizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Ramucirumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KDR/CD309, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Trontinemab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Epitumomab cituxetan is a Humanized Monoclonal antibody, expressed in Mammalian cells.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Litifilimab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
Host
CHO cells
Reactivity
Human
Applications
Conjugation
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.
